Janux Therapeutics Inc. (NASDAQ:JANX) is one of the best up and coming stocks with huge upside potential. On September 10, Truist initiated coverage of Janux Therapeutics with a Buy rating and $100 price target. Truist believes that the company’s masking platform has the potential to overcome the limitations of T-cell engagers in solid tumors by improving safety and efficacy through tumor-activated masking. For Q2 2025, Janux reported a net loss of $33.9 million, which is an increase from the $6.0 million ...

Truist Securities launched its coverage of Janux Therapeutics (NASDAQ:JANX) with a Buy recommendation and a $100 target on Wednesday, citing a catalyst-rich period for the cancer drug developer during the second half of the year. Its bullish view comes as ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40475 Janux Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 82-2289112 | ...

Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights SAN DIEGO, August 7, 2025 – Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today reported financial results for the second quarter ended J ...

Group 1 - Janux Therapeutics (NASDAQ: JANX) has garnered significant interest from investors, alongside various buy-out rumors [1] - The company specializes in the research and development of novel Cell & Gene Therapies (CGT) aimed at addressing multiple clinical needs [1] - The analysis will focus on biotechnology, pharmaceutical, Medtech, and healthcare stocks, leveraging expertise in life sciences to evaluate the potential of new treatments [1]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40475 Janux Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 82-2289112 | ...

Exhibit 99.1 Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights SAN DIEGO, May 8, 2025 – Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the first quarter ended March 31, 2025, and provided a busines ...

Group 1 - Janux Therapeutics (JANX) is identified as an early-stage biotech company with a strong pipeline focused on innovative cancer treatments that enhance the immune system's ability to identify and eliminate cancer cells [1] - The company is currently developing a new type of cancer therapy, which is positioned to potentially transform cancer treatment approaches [1] Group 2 - The article does not provide specific financial metrics or performance data related to Janux Therapeutics [2] - There are no detailed insights into the competitive landscape or market positioning of Janux Therapeutics within the biotech industry [2]

Immunotherapy Development - Janux Therapeutics is developing tumor-activated immunotherapies through two bispecific platforms: TRACTr and TRACIr, targeting solid tumors and aiming to minimize safety concerns [24]. - The company is generating additional unnamed TRACTr and TRACIr programs for future development, with some already at the development candidate stage [31]. - Janux's strategy focuses on leveraging its proprietary technology to transform cancer treatment and overcome the limitations of current immunotherapies [38]. - The TRACTr and TRACIr platforms are designed to limit activity to tumor sites, reducing the risk of on-target, healthy tissue toxicity and potentially extending half-lives in serum [44][53]. - The TRACTr platform technology allows for the development of new candidates against a variety of targets, with the first three programs achieving antibody identification and masked tumor-binding domain development in less than six months [40]. - The company is developing multiple TRACTr programs targeting solid tumors with high prevalence, including mCRPC, CRC, and NSCLC [77]. - The company believes that the TRACTr platform technology can improve pharmacokinetics and reduce CRS toxicity compared to existing therapies [88]. Clinical Trials and Results - The first clinical candidate, JANX007, is in a Phase 1 trial for metastatic castration-resistant prostate cancer (mCRPC) and has shown meaningful PSA level drops and a favorable safety profile [24]. - The second clinical candidate, JANX008, targets EGFR and is being studied in a Phase 1 trial for multiple solid cancers, with early data indicating anti-tumor activity and low-grade treatment-related adverse events [24]. - The first patient for the JANX008 trial was dosed in April 2023, with positive early data announced in February 2024 [34]. - The company announced updated interim clinical data for JANX007, showing meaningful and prolonged PSA drops and a favorable safety profile, with CRS and TRAEs primarily limited to Cycle 1 and lower grades [40]. - The first patient was dosed with EGFR-TRACTr JANX008 in April 2023, and positive early data indicated anti-tumor activity in multiple tumor types with low-grade CRS and predominantly low-grade TRAEs [40]. - The first patient was dosed with PSMA-TRACTr in a Phase 1 clinical trial for mCRPC in October 2022, with updated interim data showing meaningful PSA drops and a favorable safety profile [97]. - In the early cohorts, Grade 1 CRS was observed in only two subjects out of 11, with no Grade 2 or higher CRS reported, indicating a favorable safety profile [140]. Collaboration and Financials - Janux has a strategic collaboration with Merck, which includes potential payments of up to $500.5 million per target, plus royalties on sales from the collaboration [36]. - The Merck Agreement includes a one-time upfront payment of $8.0 million for each of the two Collaboration Targets, with potential milestone payments totaling up to $285.0 million collectively [159]. - Tiered royalty payments from Merck range from low single-digit to low teens percentage on annual net sales for licensed products, starting upon the first sale in each country [160]. - The Cell Line License Agreement with WuXi Biologics includes a non-refundable, one-time license fee of $0.2 million and potential royalty payments based on net sales of licensed products [163]. Manufacturing and Cost Efficiency - The TRACTr and TRACIr platforms are expected to offer a lower cost of goods due to their manufacturability resembling that of monoclonal antibodies [30]. - The manufacturing process for TRACTr and TRACIr molecules allows for lower cost-per-dose compared to monoclonal antibodies, with high solubility and good stability [142]. - The TRACTr and TRACIr platforms are designed to be manufacturable at a relatively lower cost, closely resembling the development processes used for monoclonal antibodies [53]. Safety and Efficacy - The TRACTr and TRACIr platforms are designed to reduce cytokine release syndrome (CRS) and on-target healthy tissue toxicity, which are significant limitations of existing TCEs [26]. - The proprietary albumin-binding domain in TRACTrs and TRACIrs is intended to increase serum half-life, with the EGFR-TRACTr demonstrating a half-life of over 100 hours compared to approximately one hour for the corresponding EGFR-TCE [67]. - The EGFR-TRACTr product candidate demonstrated an 8,500-fold shift in activating T cell killing of EGFR-expressing tumor cells when masked compared to unmasked conditions [131]. - Dosing of the EGFR-TRACTr at 100µg/kg resulted in minimal inflammatory cytokine release, compared to a greater than 20-fold increase in IL-6 with the unmasked EGFR-TCE [134]. Patent and Regulatory Landscape - As of February 14, 2025, the company owns 29 pending U.S. provisional and non-provisional patent applications, three U.S. patents, nine pending patent applications filed under the Patent Cooperation Treaty (PCT), and 94 foreign patent applications [168]. - The company has two U.S. non-provisional patent applications and five foreign patent applications directed to compositions of its TRACTr and TRACIr platform technologies applicable across product candidates for PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008) programs [168]. - The company intends to pursue patent protection directed to compositions, methods of use, methods of making, dosing, and formulations for its product candidates and processes [169]. - The FDA review process for a biologic includes submission of a Biologics License Application (BLA) after extensive preclinical studies and clinical trials [175]. - The FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of a biologic before approval [31]. - The FDA may impose conditions on approval that restrict distribution or use of the product based on post-marketing findings [208].

Financial Performance - Janux reported $1.03 billion in cash, cash equivalents, and short-term investments as of December 31, 2024, compared to $344.0 million at the end of 2023, representing a 200% increase[10]. - The net loss for Q4 2024 was $20.2 million, compared to $11.8 million in Q4 2023, and the total net loss for the year was $69.0 million, up from $58.3 million in 2023, marking an 18.5% increase[10]. - Janux's total assets increased to $1.06 billion as of December 31, 2024, compared to $380.4 million at the end of 2023, reflecting a significant growth in the company's financial position[14]. Research and Development - Research and development expenses for Q4 2024 were $20.8 million, up from $12.2 million in Q4 2023, and total R&D expenses for the year were $68.4 million, compared to $54.9 million in 2023, reflecting a 24.5% year-over-year increase[10]. - Janux plans to provide updates on JANX007 and JANX008 data in 2025, with ongoing enrollment in both Phase 1 clinical trials[4]. - The company anticipates hosting an R&D Day in 2025 to disclose new programs moving toward the clinic[4]. Clinical Trials - Positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 showed a 100% best PSA50 response rate and 63% best PSA90 declines among 16 patients as of November 15, 2024[5]. Management Changes - Zachariah McIver, D.O., Ph.D. was promoted to Chief Medical Officer, bringing over 15 years of clinical research experience to lead Janux's clinical programs[6]. Capital Raising - The company raised approximately $402.5 million in gross proceeds from an underwritten offering of common stock and pre-funded warrants in December 2024[5]. General and Administrative Expenses - General and administrative expenses for Q4 2024 were $8.2 million, compared to $6.4 million in Q4 2023, and total G&A expenses for the year were $41.0 million, up from $26.1 million in 2023, indicating a 56.9% increase year-over-year[10].